Open-house biologic discount agreements for Denosumab 2025-31

This is an Open-House procedure for Denosumab rebate contracts (Rabattverträge) under §130a Abs. 8 SGB V, organized by Techniker Krankenkasse and other health insurance funds. Originally two lots (60mg and 120mg), but Lot 1 (60mg) was terminated early as of 30.06.2026. Only Lot 2 (120mg) remains active for new participants. The procedure is a continuous open-house: any eligible pharmaceutical entrepreneur can join at any time until the contract end (30.11.2027). No estimated values or award criteria with weights are provided. Eligibility is restricted to pharmaceutical entrepreneurs with a valid marketing authorization for the respective product and who meet reliability criteria. Submission is via email (with qualified electronic signature) or postal mail. The notice explicitly states this is not a public procurement but an open-house arrangement, so procurement law remedies are not applicable; disputes go to social courts.